Laboratory Services
KRAS Mutation Analysis
Print this pageUpdated Test Information:
| Test Description |
KRAS Mutation Analysis
|
|
|---|---|---|
| Synonym(s) |
KRAS, K-RAS, RAS, KRAS Gene Sequencing, KRAS Exons 2-4 (includes G12C mutation) |
|
| Test ID |
KRASPCR |
|
| General Information |
Testing is recommended in colorectal cancer as mutations are associated with resistance and shorter overall survival with EGFR-antagonist therapies such as cetuximab or panitumumab. Testing is available separately or in combination with BRAF, HRAS and NRAS in the RAS/RAF Panel. KRAS testing in non-small cell lung cancer may provide prognostic information, predict poor response to EGFR tyrosine kinase inhibitors, and inform on possible response to targeted therapy such as sotorasib. |
|
| Specimen Type |
FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives. |
|
| Required Information |
Complete the Incyte Diagnostics requisition with the patient's demographics, ordering physician, and a copy of the pathology report. |
|
| Stability |
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. |
|
| Department (code) |
Molecular Pathology |
|
| Estimated TAT |
8 Days |
|
| Retention |
Extracted DNA is kept for 30 days. |
|
| CPT Code(s) |
81275 |
|
| Performing Lab |
NeoGenomics Laboratories |
